

# 1 Endocrine therapy use and the risk of cardiovascular disease in 2 postmenopausal breast cancer survivors: two cohort studies in the 3 UK and US

4 Anthony Matthews, *research fellow (0000-0002-1290-271X)*<sup>1,2,3</sup>, Sharon Peacock Hinton<sup>2</sup>, *research*  
5 *associate*, Susannah Stanway<sup>4</sup>, *consultant in medical oncology*, Alexander R Lyon<sup>5,6</sup>, *clinical senior*  
6 *lecturer*<sup>3</sup>, Liam Smeeth<sup>1</sup>, *professor*, Jennifer L. Lund<sup>2\*</sup>, *assistant professor*, Krishnan Bhaskaran<sup>1\*</sup>,  
7 *professor*.

8 \*Equal contribution

9

10 <sup>1</sup>Department of Non-Communicable Diseases Epidemiology, London School of Hygiene and Tropical  
11 Medicine, London, WC1E 7HT, UK; <sup>2</sup>Department of Epidemiology, Gillings School of Global Public  
12 Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; <sup>3</sup>Unit of  
13 Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden;  
14 <sup>4</sup>Royal Marsden Hospital, London, SW3 6JJ, UK; <sup>5</sup>National Heart and Lung Institute, Imperial College  
15 London, London, SW3 6LY, UK; <sup>6</sup>Royal Brompton Hospital, London, SW3 6NP, UK.

16

17 **Corresponding author:** Anthony Matthews: Unit of Epidemiology, Institute of Environmental  
18 Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden; [anthony.matthews@ki.se](mailto:anthony.matthews@ki.se); +4670  
19 2186973

20 **Abstract word count:** 310

21 **Manuscript word count:** 3476

22

23

# 1 WHAT THIS PAPER ADDS

## 2 What is already known on this topic

- 3 • It is known that tamoxifen use increases venous thromboembolism risk, but evidence for  
4 other cardiovascular outcomes is less clear.
- 5 • Patterns of results are suggestive of a lower risk of coronary heart disease outcomes with  
6 tamoxifen compared to both aromatase inhibitor use and no tamoxifen or placebo, but  
7 cardiovascular events are often a secondary consideration and inconsistently reported in  
8 trials, and most observational studies use composite cardiovascular definitions, ignoring  
9 potentially differential effects on specific cardiovascular outcomes.

## 10 What this study adds

- 11 • Among postmenopausal women with breast cancer, we found an increased risk of several  
12 cardiovascular diseases in aromatase inhibitor compared with tamoxifen users across two  
13 countries, which appeared to be driven by protective effects of tamoxifen, rather than toxic  
14 effects of aromatase inhibitors. We also found the known increased venous  
15 thromboembolism risk in tamoxifen users.
- 16 • There was no evidence that aromatase inhibitors or tamoxifen increases cardiovascular  
17 disease risk, other than the known increased venous thromboembolism risk with tamoxifen  
18 use. However, there was an apparent protective effect of tamoxifen on other cardiovascular  
19 outcomes.

20

21

# 1 ABSTRACT

2 **Objective:** Examine the effect of tamoxifen and aromatase inhibitors on 12 clinically relevant  
3 individual cardiovascular outcomes in postmenopausal female breast cancer survivors using large-  
4 scale datasets from the UK and US.

5 **Design:** Two prospective cohort studies

6 **Setting:** Population-based using data from the UK Clinical Practice Datalink linked with Hospital  
7 Episode Statistics (2002-2016), and the US Surveillance, Epidemiology and End Results-Medicare  
8 database (2008-2013).

9 **Participants:** 10005 and 22027 postmenopausal women with breast cancer in the UK and US  
10 respectively.

11 **Exposures:** Aromatase inhibitor compared with tamoxifen use; the US cohort additionally included a  
12 comparison with an “unexposed” group of women with oestrogen or progesterone receptor positive  
13 breast cancer but no endocrine therapy use.

14 **Outcomes:** 12 clinically relevant individual cardiovascular outcomes (and two composite coronary  
15 and venous thromboembolic outcomes)

16 **Results:** In both the UK and the US, there was evidence of an increased risk of coronary artery  
17 disease in aromatase inhibitor compared with tamoxifen users (UK incidence rate: 10.18 vs 6.87 per  
18 1000 person-years, HR: 1.29, 0.94-1.76; US incidence rate: 35.26 vs 26.95 per 1000 person-years, HR:  
19 1.29, 1.06-1.55), but the US data showed no increase in risk compared with the unexposed group  
20 (incidence rate for tamoxifen vs unexposed: 26.95 vs 38.70 per 1000 person-years, HR: 0.74, 0.60-  
21 0.92; incidence rate for aromatase inhibitors vs unexposed: 35.26 vs 28.70, HR: 0.96, 0.83-1.10).  
22 Similar patterns were seen for other cardiovascular outcomes such as arrhythmia, heart failure, and  
23 valvular heart disease. As expected, there were more venous thromboembolic events in tamoxifen  
24 users compared with both aromatase inhibitor users and those unexposed. There was a high degree  
25 of consistency between results in the two countries.

26 **Conclusions:** Increased risks of several cardiovascular diseases among aromatase inhibitor compared  
27 with tamoxifen users appeared to be driven by protective effects of tamoxifen, rather than toxic  
28 effects of aromatase inhibitors. We also confirmed the known increased risk of venous  
29 thromboembolic events in tamoxifen users.

## 1 BACKGROUND

2 Breast cancer is the most common cancer among women worldwide; 83% of breast cancer patients  
3 are diagnosed with oestrogen or progesterone receptor positive disease (ER/PR+) and are  
4 recommended endocrine therapies to minimise risk of recurrence.[1] Tamoxifen reduces the rate of  
5 breast cancer recurrence by nearly half, regardless of menopausal status,[2] but since 2006  
6 aromatase inhibitors (AI) are also recommended to postmenopausal women due to greater efficacy  
7 over tamoxifen.[3] However, it is hypothesised that these drugs may affect cardiovascular disease  
8 (CVD) risk through pathways including suppression of protective effects of circulating oestrogen,[4]  
9 changes in cholesterol,[5, 6] and reduction of antithrombin levels.[7]

10  
11 A recent systematic review collated all evidence for the risk of CVD for users of tamoxifen, AIs, and  
12 the comparative risk between the two drugs.[8] It suggested that tamoxifen use increases risk of  
13 venous thromboembolic events, but evidence for other outcomes was less clear. Patterns of results  
14 are suggestive of a lower risk of coronary heart disease outcomes with tamoxifen compared to both  
15 AI use and no tamoxifen or placebo, but CVD events are often a secondary consideration and  
16 inconsistently reported in trials, and most observational studies use composite CVD definitions,  
17 ignoring potentially differential effects on specific CVDs.

18  
19 Given the uncertainty and clinical importance, we aimed to examine the effects of tamoxifen and AIs  
20 on 12 clinically relevant individual CVD outcomes (and two composite outcomes) in postmenopausal  
21 female breast cancer survivors using two large-scale datasets from both the UK and US.

## 22 METHODS

### 23 Study design and data sources

24 We assembled two separate and nationally representative cohorts of women with incident  
25 postmenopausal breast cancer using prospectively collected data from large UK and US electronic  
26 healthcare databases. In the UK, we used Clinical Practice Research Datalink primary care data (CPRD  
27 GOLD) and linked Hospital Episode Statistics (HES). [9] In the US, we used the Surveillance,  
28 Epidemiology, and End Results program (SEER) and Medicare linked database.[10] Full detail on  
29 these data sources are available in Appendix 1.

30  
31  
32

# 1 **Study populations**

2 Differences between the study populations were largely driven by differences in data available  
3 within the two cohorts, which are fully explained in Appendix 2.

## 4 UK cohort

5 We identified women with linked CPRD and HES data over 54 years (median age of the menopause  
6 in Europe [11]), with incident breast cancer in CPRD (after at least one year of CPRD follow-up), who  
7 initiated AIs or tamoxifen in primary care after their diagnosis, from 1<sup>st</sup> January 2002 (date from  
8 which preliminary analysis showed that third generation AIs came into widespread use) to 31<sup>st</sup>  
9 March 2016 (latest CPRD and HES linkage). Follow-up began at the latest of one year after breast  
10 cancer diagnosis, or first AI or tamoxifen prescription (hereafter index date). Women were excluded  
11 if prior to their index date they: died, transferred out of the CPRD, had any other cancer diagnosis, or  
12 were diagnosed with the CVD event of interest (at any point prior to index date).

## 13 US cohort

14 We identified women over 65 years with incident ER/PR+ and stage 1-3 breast cancer and  
15 continuous Medicare Parts A, B and D enrolment (and no managed care coverage) for the 12-months  
16 prior to the month of cancer diagnosis from 1<sup>st</sup> January 2008 (Medicare Part D data are available  
17 from 2007) and 31<sup>st</sup> December 2013 (last capture of cancer cases in SEER). Women with an  
18 endocrine therapy prescription prior to their breast cancer diagnosis were excluded. Follow up  
19 began one year after the date of breast cancer (hereafter index date). Women were excluded if prior  
20 to their index date they: died, discontinued from Medicare Parts A, B, or D, had any other cancer  
21 diagnosis, or were diagnosed with the CVD event of interest (within a 3-year look back period to  
22 ensure likelihood of capturing a prior event was not dependent on age as Medicare follow up starts  
23 at 65 years).

## 25 **Exposure, outcomes, and covariates**

26 Tamoxifen and AI exposures were identified using prescription codes in the UK (available at  
27 <https://doi.org/10.17037/DATA.177>), and National Drug Codes (NDCs) and Healthcare Common  
28 Procedural Coding System (HCPCS) procedure codes in the US (Appendix 3). The primary exposure  
29 was ever use of tamoxifen, ever use of AI, or ever use of both drugs; the US study included an  
30 additional category of no exposure to any endocrine therapy (which did not exist in the UK study,  
31 because receipt of endocrine therapy was an inclusion criterion). Exposure was time-updated to  
32 indicate a woman had been exposed to both drugs if they switched endocrine therapies during  
33 follow-up. The baseline exposure group was classified as ever exposure to tamoxifen for the ever AI

1 vs tamoxifen analyses in both the UK and US, whereas the baseline exposure group was changed to  
 2 no exposure to any endocrine therapy for the ever AI/tamoxifen vs unexposed analyses that were  
 3 only possible in the US. In secondary analyses, we considered time-updated current exposure to  
 4 endocrine therapy, categorised as current tamoxifen use, current AI use, no current therapy and  
 5 prior AI use, no current therapy and prior tamoxifen use only, and (in the US study only) no current  
 6 or past endocrine therapy. A drug exposure was continuous if a further prescription for the same  
 7 endocrine therapy followed within 30 days of the end of the previous prescription date plus the days  
 8 of drug supplied. Further information is in Appendix 4, and visualisations of exposure categorisations  
 9 in Appendices 5 and 6.

10

11 The main CVD outcomes were: coronary artery disease (angina, myocardial infarction (MI),  
 12 revascularisation procedures, sudden cardiac arrest (SCA)); peripheral vascular disease (PVD);  
 13 stroke; arrhythmia; heart failure (HF, including cardiomyopathy); pericarditis, valvular heart disease  
 14 (VHD); and venous thromboembolism (VTE) (deep vein thrombosis (DVT), pulmonary embolism  
 15 (PE)). Composite CVD outcomes and individual components of the composite outcomes were  
 16 analysed separately. Events were identified through clinical diagnoses using NHS Read codes in the  
 17 CPRD and International Classification of Disease (ICD), 10<sup>th</sup> edition codes in HES in the UK (available  
 18 at <https://doi.org/10.17037/DATA.177>), and ICD-9 and Healthcare Common Procedure Coding  
 19 System (HCPCS) codes in the US study (Appendix 7).

20

21 In both studies, we adjusted for age, cardiovascular history and risk factors, use of cardio-protective  
 22 medications, other comorbidities, time since index date, and calendar year. In the UK we were  
 23 additionally able to adjust for smoking, alcohol use, body mass index, and index of multiple  
 24 deprivation (a measure of socioeconomic status); in the US study we were additionally able to adjust  
 25 for race, region and use of anti-cancer therapies. A full comparison of the covariates considered in  
 26 the UK and US is in Appendix 8. Algorithms to define confounders in the UK are in Appendix 9, and  
 27 code lists used for variable definitions are at <https://doi.org/10.17037/DATA.177>. Codes used to  
 28 identify prescriptions in the US are in Appendix 10.

29

### 30 **Statistical Analysis**

31 Observation time began at index date and ended at the earliest of: a CVD event of interest; diagnosis  
 32 of another (non-breast) cancer; death; transfer out of CPRD/end of Medicare Parts A, B, or D  
 33 enrolment; or end of study period (31<sup>st</sup> March 2016 in UK which is the last available CPRD collection

date, and 31<sup>st</sup> December 2014 in US which is the last available Medicare collection date).

Separate analyses were conducted in UK and US data. Distributions of baseline characteristics of patients at index date were described. Number of events and crude incident rates of each outcome of interest by exposure were calculated. Cox proportional hazards regression models with an underlying age timescale were fitted for each outcome of interest to obtain unadjusted hazard ratios (HRs) and 95% CIs for the association between endocrine therapy use and outcome; those with a diagnosis of the specific outcome of interest before the index date were excluded from the analysis for that outcome. All covariates were then added to obtain fully-adjusted HRs and 95% CIs. The analysis was repeated for the primary and secondary exposure definitions. Using the primary exposure definitions in each country, we then fitted interactions to investigate effect modification by current age (54-69, 70+ in the UK; 66-84, 85+ in the US); time since index date (0-1 years, 1-3 years, 3+ years); and history of any CVD prior to index date for the coronary artery disease (composite), arrhythmia, stroke, pericarditis (US only), heart failure, VHD, and VTE (composite) outcomes (interactions were not investigated for other outcomes due to limited power). Women with missing data (8.7% in the UK, and 5.1% in the US) were excluded from all analyses (complete case analysis), which is valid in a regression context if missingness is conditionally independent of the outcome.[12]

### ***Sensitivity analyses***

To ensure comparability between the UK and US, the main analyses were repeated with the study populations and covariates modified to be as similar as possible. Further details in Appendix 11. Furthermore, in case of misclassification of exposure, the grace period used to define a continuous prescription was extended from 30 days to 3 months, 6 months, and 1 year in the analyses of current endocrine therapy exposure. Finally, a post-hoc quantitative bias analysis explored potential unmeasured confounding in the large estimated protective effect of tamoxifen use on the risk of MI (Appendix 12).[13]

Patients and the public were not involved at any point during this research.

## **RESULTS**

The UK study included 10005 women, with 4716 (47%) initially prescribed tamoxifen and 5289 (53%) initially prescribed an AI (Table 1, flow diagram in Figure 1). Mean follow-up from index date for

individual CVD outcomes ranged from 4-4.1 years. The US study included 22027 women, with 4667 (22%), 2286 (10%) and 15074 (68%) initially filling no endocrine therapy, tamoxifen, and an AI respectively (Table 2, flow diagram in Figure 1). Mean follow-up from index date for individual CVD outcomes ranged from 2.3-2.5 years.

## **Ever Exposure analyses**

### ***Ever AI vs Tamoxifen use***

In both the UK and US settings, there was a higher observed rate of most CVDs, excluding VTE outcomes, among those ever exposed to an AI compared with tamoxifen (Appendices 13-14). In adjusted analyses, there was strong evidence of a higher risk of heart failure in AI compared with tamoxifen users in the UK (HR: 1.68, 1.24-2.26, Figure 2), which was not replicated in the US (HR: 0.96, 0.83-1.12). Other adjusted HRs were consistent between the two settings; there was evidence in one or both settings that AI users compared with tamoxifen users had higher risk of coronary artery disease, myocardial infarction, arrhythmia, pericarditis, and VHD (HRs ranged from 1.29-3.25 in the UK, and 1.21-1.81 in the US, Figure 2) and lower risk of deep vein thrombosis (UK HR: 0.63, 0.43-0.93; US HR: 0.81, 0.50-1.09).

### ***Ever AI/Tamoxifen use vs unexposed***

The US study included women without exposure to either endocrine therapy; observed rates of most CVDs, excluding VTE, were lower in both the tamoxifen and AI groups compared with the unexposed group, while VTE outcome rates were higher in the endocrine therapy groups (Appendix 14). The patterns were similar in adjusted analyses (Figure 3); there was evidence that tamoxifen users had lower risks than unexposed women for coronary artery disease, myocardial infarction, stroke, arrhythmia, pericarditis, and VHD (HRs ranged from 0.37-0.87); HR point estimates for AI users vs unexposed were also in the protective direction for all non-VTE CVD outcomes, but in most cases were closer to the null than for tamoxifen, and with confidence intervals including no association. There was weak evidence of higher risk VTE in tamoxifen users compared with the unexposed (HR: 1.39, 0.98-1.98), but little evidence of a difference for AI users vs unexposed (HR: 1.14, 0.86-1.52).

## **Current exposure analyses**

Results for the analysis of current endocrine therapy use were consistent with the findings in the primary ever exposure analyses, and were consistent between the UK and US (Appendices 15-18).

## **Effect modification**



There was no strong evidence of effect modification by age, time since index date, or prior CVD in the UK or US (Appendices 19-20), though there were few events within strata, limiting precision. There was a suggestion in UK data that the raised risk of coronary artery disease in AI compared with tamoxifen users diminished over time ( $p=0.02$ ), but no corresponding evidence in US data.

## Sensitivity analyses

Following modification of study populations, methodology, and covariates in the UK and US to make them as similar as possible, the risk of all CVDs associated with ever and current AI compared to tamoxifen use were generally in the same direction, albeit with less precision in UK data (Appendices 21-22). However, the discrepant results for heart failure between the two cohorts persisted.

Altering the grace period used to define continuous drug use had little effect on results (Appendices 23-24).

Quantitative bias analyses suggest that unmeasured confounding was unlikely to fully explain the large HR for the effect of ever tamoxifen use on the risk of MI (Appendix 25).

## DISCUSSION

These two population-based cohort studies using UK and US data are the first to apply similar methodology to two large populations to assess the effects of endocrine therapies on a range of CVD outcomes in postmenopausal women with breast cancer. Both countries' results suggested a higher risk of several CVD outcomes in AI compared with tamoxifen users, with no evidence that any other characteristics, including previous CVD, modified the estimated effect. However, comparisons with women exposed to neither drug suggest that this is driven by a decreased risk of these CVD outcomes in tamoxifen users; and there was no evidence for any cardiotoxicities associated with AI use compared with those unexposed to endocrine therapy. In both the UK and the US, tamoxifen users were consistently at higher risk of VTE outcomes than both AI users and those unexposed to endocrine therapy.

The protective effect of tamoxifen on some CVDs might be explained by the drug's effect on lipid levels. Previous studies have found tamoxifen to reduce total serum cholesterol (10-15%) and low-density lipoprotein cholesterol (15-22%). [5, 6] It has also been suggested that AIs could increase the risk of CVD compared with tamoxifen through depleting oestrogen-mediated protective CVD

1 effects,[4] but several trials have compared hypercholesterolemia between AI and tamoxifen users,  
2 with inconclusive results.[14-16]

### 4 **Comparison to other studies**

5 A recent meta-analysis of trials reported an increased risk of a composite CVD outcome, excluding  
6 VTE, in tamoxifen compared with AI users (RR: 1.18, 1.05-1.33),[17] with results suggestive of a  
7 cardio-protective effect of tamoxifen, consistent with the results of this study.

8  
9 Several studies have focused on more specific CVD outcomes, and MI, stroke, heart failure, and VTE  
10 are the outcomes with the largest body of previous evidence, but there is little evidence for the  
11 other specific CVD outcomes that we explored. Most (4/5) previous studies directly comparing the  
12 risk of MI in AI and tamoxifen users have reported an increased risk in AI users, similar to our results  
13 (RRs ranged from 0.99-2.02).[18-22] Two previous trials and five observational studies have  
14 compared MI risk in tamoxifen users with non-use/placebo, with 4/7 studies finding a reduced risk in  
15 tamoxifen users (RRs ranged from 0.20-0.83);[23-29] two analogous studies of AI use versus placebo  
16 or non-use found no association.[16, 28] Six studies (five trials and one observational) directly  
17 compared the risk of stroke in AI and tamoxifen users, but associations in both directions have been  
18 reported.[20, 22, 30-33] Three out of five studies (one trial and four observational) comparing  
19 tamoxifen use with non-use/placebo found a protective association with stroke, as in our study (RRs  
20 ranged from 0.52-0.81).[23, 26-28, 34] In the present analysis, we found AI users to be at reduced  
21 risk of stroke compared to unexposed women; one previous study found a similar association but a  
22 second reported the opposite.[16, 28]. Two previous studies (one trial and one observational) have  
23 reported results for the comparison between AI and tamoxifen use on the risk of heart failure, [30,  
24 33] for which we reported discrepant results between the UK and US. One reported an increased risk  
25 in AI users and the other reported no association. The discrepant results in our study could be due to  
26 residual confounding by variables not available in both datasets (cancer therapies in the UK, and  
27 lifestyle factors in the US), or the nature of the data sources (routinely collected records in the UK  
28 and claims in the US).

29  
30 Six previous trials compared the risk of VTE in AI and tamoxifen users, with five reporting a  
31 decreased risk in AI compared with tamoxifen users (RR ranged from 1.25-0.61), as reported in both  
32 UK and US data in this study.[18, 20, 22, 30, 35, 36] Six out of eight studies (five trials and three  
33 observational) also reported an effect estimate that suggested an increased risk in tamoxifen users  
34 (RRs ranged from 1.64-7.10), which is in the same direction, but larger than the effect in US data

here. One observational study reported an increased risk of VTE in AI users (RR: 1.84, 1.11-3.04), but US data suggested no association.

#### Strengths and limitations

A major strength of this study was the use of two large data sources from different countries, with complementary strengths and different limitations. By including data from study populations with different characteristics, we could look for consistency in observed associations, and conduct different comparisons, notably between classes, and with unexposed patients. We were also able to assess the relationships between endocrine therapy treatments and a wide range of CVD outcomes, rather than the composite and individual CVD outcomes in many previous studies. We were also able to account for several important confounders such as potentially cardio-toxic treatments (anthracyclines and trastuzumab, in US data) and lifestyle factors (BMI, smoking, and alcohol, in UK data); although no confounders materially changed the crude effect estimate when adjusted for individually in the ever exposure analyses in either the UK or US (Appendices 26 and 27). As the CPRD broadly represents the UK population, and SEER-Medicare includes a large, diverse population of older women diagnosed with breast cancer, results are generalisable to women diagnosed with ER/PR+ breast cancer in both the UK, US, and other developed populations due to the homogenous indication of endocrine therapy worldwide.

In the UK, ER/PR status was not available, but it is likely that breast cancers were ER/PR+ as such a diagnosis is a prerequisite of being prescribed endocrine therapies. The unavailability of ER/PR status also meant that we could not identify a group of untreated patients diagnosed with ER/PR+ breast cancer in the UK. Furthermore, CPRD captures prescriptions at the point of issue, but we do not know if prescriptions were filled, which could lead to potential misclassification of exposure. However, descriptive analyses using a 6 month grace period to define a continuous prescription indicated that 97% of women continued to be prescribed within 1 year of starting, 95% within 3 years, and 85% within 5 years.

In the US, the relatively high proportion of non-initiators of endocrine therapy (21%) in women with ER/PR+ was similar to the proportion of non-initiators reported in a previous study.[17] Reasons for non-initiation may include frailty, poor CVD preventative care, and high BMI, introducing possible residual confounding, especially given lack of information on smoking and BMI in US data. Although quantitative bias analyses suggest it is unlikely that residual confounding explains all of the large observed protective associations between tamoxifen use and several CVD outcomes, these

1 associations may have been exaggerated, and the smaller observed associations between AI use and  
2 outcomes could be driven by such confounding. Comparisons to non-user groups are often more  
3 subject to confounding than comparisons to groups utilizing similar medications (i.e. AI vs  
4 tamoxifen).[37] Some caution should be taken in the interpretation of the comparisons with non-  
5 users, and these results warrant further investigation.

## 7 **Implications**

8 Our results indicated no excess cardiotoxicities of endocrine therapy, other than the raised risk of  
9 VTE with tamoxifen. There was no evidence of raised risk of any CVD with AI use, including in  
10 stratified results restricted to those with prior CVD, suggesting that a history of cardiovascular  
11 disease should not be a contraindication for prescription of an AI. It is likely that AIs will continue to  
12 be the preferred endocrine therapy of choice in postmenopausal survivors of ER/PR+ breast cancer  
13 given its superior efficacy over tamoxifen. However, in women at a high CVD risk, it would be  
14 informative to know if any cardio-protective effects of tamoxifen might offset the superior reduction  
15 in risk of breast cancer recurrence with AIs. Further knowledge of the risk-benefit balance of the two  
16 endocrine therapies in terms of effects on cancer survival and cardiovascular outcomes in sub-  
17 groups of women would help guide individual-level prescribing decisions.

## 19 **CONCLUSION**

20 Among postmenopausal women diagnosed with ER/PR+ breast cancer, we found convincing  
21 evidence of increased risks of several CVDs in AI compared with tamoxifen users. However, these  
22 associations appeared to be driven by protective effects of tamoxifen, rather than any toxic effects  
23 of AIs. There was no evidence that either drug type causally increased the risks of CVD outcomes,  
24 other than the known increased VTE risk with tamoxifen use. This information will help to inform  
25 and better understand the risk-benefit balance of these widely used endocrine therapies.

26

## 1 FOOTNOTES

2 The corresponding author has the right to grant on behalf of all authors and does grant on behalf of  
3 all authors, an exclusive license (or non-exclusive for government employees) on a worldwide basis  
4 to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions  
5 and any other BMJ PGL products and sub-licenses such use and exploit all subsidiary rights, as set out  
6 in our license.

## 7

## 8 Conflicts of interest

9 AM, SPH, and JL have nothing to disclose. SS reports personal fees from Roche, Clinigen, Eli Lilly, and  
10 Novartis, outside the submitted work. AL reports personal fees from Servier, Novartis, Pfizer, Roche,  
11 Ferring Pharmaceuticals, Clinigen Group, Boehringer Ingelheim, Amgen, Eli Lilly, and BMS, outside  
12 the submitted work. LS reports grants from Wellcome, during the conduct of the study; grants from  
13 Wellcome, MRC, NIHR, BHF, Diabetes UK, and grants and personal fees from GSK, outside the  
14 submitted work; and is a trustee of the British Heart Foundation. KB reports grants from Wellcome  
15 Trust and the Royal Society, during the conduct of the study.

## 16

## 17 Contributions

18 Study designs were decided on by AM, JL, and KB. AM and SPH carried out data extraction. AM  
19 carried out all analyses. AM wrote the first draft. All authors contributed to further drafts and  
20 approved the final manuscript.

## 21

## 22 Funding

23 This study was supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and  
24 the Royal Society (grant No 107731/Z/15/Z) held by KB. The Wellcome Trust and the Royal Society  
25 had no role in the design, analysis, or writing up of this study.

## 26 Ethical approval

27 The UK study was approved by the ethics board at the London School of Hygiene and Tropical  
28 Medicine (project ID: 12025), and the US study was gained IRB approval at the University of North  
29 Carolina (study number: 17-1766)

## 30

## 31 Data sharing

32 Data from either the UK or US studies are not openly accessible, but can be gained through an  
33 application to the CRPD and SEER-Medicare respectively.

34

1    **Transparency**

2    The lead author affirms that the manuscript is an honest, accurate, and transparent account of the  
3    study being reported; that no important aspects of the study have been omitted; and that any  
4    discrepancies from the study as planned (and, if relevant, registered) have been explained.

5

6

## 1 REFERENCES

- 2 1. Howlader, N., et al., *US incidence of breast cancer subtypes defined by joint hormone*  
3 *receptor and HER2 status*. J Natl Cancer Inst, 2014. **106**(5).
- 4 2. Early Breast Cancer Trialists' Collaborative, G., et al., *Relevance of breast cancer hormone*  
5 *receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis*  
6 *of randomised trials*. Lancet, 2011. **378**(9793): p. 771-84.
- 7 3. Dowsett, M., et al., *Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase*  
8 *inhibitors versus tamoxifen*. J Clin Oncol, 2010. **28**(3): p. 509-18.
- 9 4. Mendelsohn, M.E. and R.H. Karas, *The protective effects of estrogen on the cardiovascular*  
10 *system*. N Engl J Med, 1999. **340**(23): p. 1801-11.
- 11 5. Dewar, J.A., et al., *Long term effects of tamoxifen on blood lipid values in breast cancer*. BMJ,  
12 1992. **305**(6847): p. 225-6.
- 13 6. Love, R.R., et al., *Effects of tamoxifen on cardiovascular risk factors in postmenopausal*  
14 *women after 5 years of treatment*. Journal of the National Cancer Institute, 1994. **86**(20): p.  
15 1534-9.
- 16 7. Love, R.R., T.S. Surawicz, and E.C. Williams, *Antithrombin III level, fibrinogen level, and*  
17 *platelet count changes with adjuvant tamoxifen therapy*. Archives of Internal Medicine,  
18 1992. **152**(2): p. 317-20.
- 19 8. Matthews, A., et al., *Long term adjuvant endocrine therapy and risk of cardiovascular disease*  
20 *in female breast cancer survivors: systematic review*. BMJ, 2018. **363**: p. k3845.
- 21 9. Herrett, E., et al., *Data Resource Profile: Clinical Practice Research Datalink (CPRD)*. Int J  
22 Epidemiol, 2015. **44**(3): p. 827-36.
- 23 10. Warren, J.L., et al., *Overview of the SEER-Medicare data: content, research applications, and*  
24 *generalizability to the United States elderly population*. Med Care, 2002. **40**(8 Suppl): p. IV-3-  
25 18.
- 26 11. Dratva, J., et al., *Is age at menopause increasing across Europe? Results on age at*  
27 *menopause and determinants from two population-based studies*. Menopause, 2009. **16**(2):  
28 p. 385-94.
- 29 12. White, I.R. and J.B. Carlin, *Bias and efficiency of multiple imputation compared with*  
30 *complete-case analysis for missing covariate values*. Stat Med, 2010. **29**(28): p. 2920-31.
- 31 13. Lash, T.F., MP. Fink, AK., *Applying Quantitative Bias Analysis to Epidemiologic Data*. 2009:  
32 Springer.
- 33 14. Arimidex, T.A.o.i.C.T.G., et al., *Comprehensive side-effect profile of anastrozole and*  
34 *tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of*  
35 *the ATAC trial*. Lancet Oncol, 2006. **7**(8): p. 633-43.
- 36 15. Coates, A.S., et al., *Five years of letrozole compared with tamoxifen as initial adjuvant*  
37 *therapy for postmenopausal women with endocrine-responsive early breast cancer: update*  
38 *of study BIG 1-98*. Journal of Clinical Oncology, 2007. **25**(5): p. 486-92.
- 39 16. Goss, P.E., et al., *Randomized trial of letrozole following tamoxifen as extended adjuvant*  
40 *therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17*. Journal  
41 of the National Cancer Institute, 2005. **97**(17): p. 1262-71.
- 42 17. Khosrow-Khavar, F., et al., *Cardiotoxicity of aromatase inhibitors and tamoxifen in*  
43 *postmenopausal women with breast cancer: a systematic review and meta-analysis of*  
44 *randomized controlled trials*. Ann Oncol, 2017. **28**(3): p. 487-496.
- 45 18. Jakesz, R., et al., *Switching of postmenopausal women with endocrine-responsive early*  
46 *breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG*  
47 *trial 8 and ARNO 95 trial*. Lancet, 2005. **366**(9484): p. 455-62.
- 48 19. Coombes, R.C., et al., *Survival and safety of exemestane versus tamoxifen after 2-3 years'*  
49 *tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial*. Lancet,  
50 2007. **369**(9561): p. 559-70.

- 1 20. Pagani, O., et al., *Adjuvant exemestane with ovarian suppression in premenopausal breast*  
2 *cancer*. N Engl J Med, 2014. **371**(2): p. 107-18.
- 3 21. Abdel-Qadir, H., et al., *The risk of myocardial infarction with aromatase inhibitors relative to*  
4 *tamoxifen in post-menopausal women with early stage breast cancer*. Eur J Cancer, 2016. **68**:  
5 p. 11-21.
- 6 22. Arimidex, T.A.o.i.C.T.G., et al., *Effect of anastrozole and tamoxifen as adjuvant treatment for*  
7 *early-stage breast cancer: 100-month analysis of the ATAC trial*. Lancet Oncology, 2008. **9**(1):  
8 p. 45-53.
- 9 23. McDonald, C.C., et al., *Cardiac and vascular morbidity in women receiving adjuvant*  
10 *tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group*.  
11 BMJ, 1995. **311**(7011): p. 977-80.
- 12 24. Rutqvist, L.E., *Long-term toxicity of tamoxifen*. Recent Results in Cancer Research, 1993. **127**:  
13 p. 257-66.
- 14 25. Bradbury, B.D., et al., *Tamoxifen-treated breast carcinoma patients and the risk of acute*  
15 *myocardial infarction and newly-diagnosed angina*. Cancer, 2005. **103**(6): p. 1114-21.
- 16 26. Yang, T.L., et al., *Association of tamoxifen use and reduced cardiovascular events among*  
17 *asian females with breast cancer*. Circulation Journal, 2014. **78**(1): p. 135-40.
- 18 27. Hernandez, R.K., et al., *Tamoxifen treatment in Danish breast cancer patients and 5-year risk*  
19 *of arterial atherosclerotic events: a null association*. Cancer Epidemiology, Biomarkers &  
20 Prevention, 2008. **17**(9): p. 2509-11.
- 21 28. Ligibel, J.A., et al., *Risk of myocardial infarction, stroke, and fracture in a cohort of*  
22 *community-based breast cancer patients*. Breast Cancer Research & Treatment, 2012.  
23 **131**(2): p. 589-97.
- 24 29. Geiger, A.M., W. Chen, and L. Bernstein, *Myocardial infarction risk and tamoxifen therapy for*  
25 *breast cancer*. British Journal of Cancer, 2005. **92**(9): p. 1614-20.
- 26 30. Colleoni, M., et al., *Analyses adjusting for selective crossover show improved overall survival*  
27 *with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study*. J Clin Oncol, 2011.  
28 **29**(9): p. 1117-24.
- 29 31. Abo-Touk, N.A., H.A. Sakr, and A. Abd El-Lattef, *Switching to letrozole versus continued*  
30 *tamoxifen therapy in treatment of postmenopausal women with early breast cancer*. J Egypt  
31 Natl Canc Inst, 2010. **22**(1): p. 79-85.
- 32 32. Kaufmann, M., et al., *Improved overall survival in postmenopausal women with early breast*  
33 *cancer after anastrozole initiated after treatment with tamoxifen compared with continued*  
34 *tamoxifen: the ARNO 95 Study*. J Clin Oncol, 2007. **25**(19): p. 2664-70.
- 35 33. Haque, R., et al., *Cardiovascular Disease After Aromatase Inhibitor Use*. JAMA Oncol, 2016.
- 36 34. Geiger, A.M., et al., *Stroke risk and tamoxifen therapy for breast cancer*. Journal of the  
37 National Cancer Institute, 2004. **96**(20): p. 1528-36.
- 38 35. Boccardo, F., et al., *Switching to anastrozole versus continued tamoxifen treatment of early*  
39 *breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial*. Ann Oncol,  
40 2006. **17 Suppl 7**: p. vii10-4.
- 41 36. Bliss, J.M., et al., *Disease-related outcomes with long-term follow-up: an updated analysis of*  
42 *the intergroup exemestane study*. J Clin Oncol, 2012. **30**(7): p. 709-17.
- 43 37. Schneeweiss, S., et al., *Increasing levels of restriction in pharmacoepidemiologic database*  
44 *studies of elderly and comparison with randomized trial results*. Med Care, 2007. **45**(10 Supl  
45 2): p. S131-42.

46

47



**Table 1 - Characteristics of study population based on their initial exposure in the UK**

	<b>Tamoxifen</b>	<b>AI</b>	<b>Total</b>
<b>N</b>	4716 (100)	5289 (100)	10005 (100)
<b>Age (yrs)</b>			
54-59	911 (19.3)	716 (13.5)	1627 (16.3)
60-69	1850 (39.2)	1972 (37.3)	3822 (38.2)
70+	1955 (41.5)	2601 (49.2)	4556 (45.5)
Median (IQR)	68 (62-76)	70 (63-79)	69 (62-78)
<b>Year of breast cancer</b>			
2002	579 (12.3)	72 (1.4)	651 (6.5)
2003	605 (12.8)	123 (2.3)	728 (7.3)
2004	571 (12.1)	186 (3.5)	757 (7.6)
2005	512 (10.9)	289 (5.5)	801 (8)
2006	467 (9.9)	370 (7)	837 (8.4)
2007	386 (8.2)	448 (8.5)	834 (8.3)
2008	380 (8.1)	495 (9.4)	875 (8.7)
2009	290 (6.1)	533 (10.1)	823 (8.2)
2010	223 (4.7)	586 (11.1)	809 (8.1)
2011	216 (4.6)	619 (11.7)	835 (8.3)
2012	210 (4.5)	539 (10.2)	749 (7.5)
2013	174 (3.7)	504 (9.5)	678 (6.8)
2014	93 (2)	451 (8.5)	544 (5.4)
2015	10 (.2)	74 (1.4)	84 (.8)
<b>BMI (kg/m2)</b>			
<18	59 (1.3)	63 (1.2)	122 (1.2)
18-24	1693 (35.9)	1619 (30.6)	3312 (33.1)
25-29	1549 (32.8)	1801 (34.1)	3350 (33.5)
30-34	800 (17)	979 (18.5)	1779 (17.8)
≥35	345 (7.3)	548 (10.4)	893 (8.9)
Missing	270 (5.7)	279 (5.3)	549 (5.5)
Median (IQR)	26 (23-30)	27 (24-31)	27 (24-31)
<b>Smoking status</b>			
Never smoker	2423 (51.4)	2517 (47.6)	4940 (49.4)
Current smoker	503 (10.7)	482 (9.1)	985 (9.8)
Ex-smoker	1761 (37.3)	2268 (42.9)	4029 (40.3)
Missing	29 (.6)	22 (.4)	51 (.5)
<b>Alcohol use</b>			
Non drinker	618 (13.1)	613 (11.6)	1231 (12.3)
Current	3320 (70.4)	3628 (68.6)	6948 (69.4)
Ex-drinker	480 (10.2)	715 (13.5)	1195 (11.9)
Missing	298 (6.3)	333 (6.3)	631 (6.3)
<b>Systolic BP</b>			
Low/ideal	530 (11.2)	599 (11.3)	1129 (11.3)
Pre-high	1862 (39.5)	2327 (44)	4189 (41.9)
High	2314 (49.1)	2355 (44.5)	4669 (46.7)
Missing	10 (.2)	8 (.2)	18 (.2)
<b>Diastolic BP</b>			
Low/ideal	2130 (45.2)	2650 (50.1)	4780 (47.8)
Pre-high	1988 (42.2)	2058 (38.9)	4046 (40.4)
High	588 (12.5)	573 (10.8)	1161 (11.6)
Missing	10 (.2)	8 (.2)	18 (.2)
<b>IMD category</b>			
1	870 (18.4)	962 (18.2)	1832 (18.3)
2	943 (20)	1214 (23)	2157 (21.6)
3	925 (19.6)	1054 (19.9)	1979 (19.8)
4	1052 (22.3)	936 (17.7)	1988 (19.9)
5	926 (19.6)	1122 (21.2)	2048 (20.5)
Missing	0 (0)	1 (0)	1 (0)
<b>CVD related treatment before index</b>			
Statins	1100 (23.3)	1903 (36)	3003 (30)
ACEI	1195 (25.3)	1823 (34.5)	3018 (30.2)
CCB	1195 (25.3)	1764 (33.4)	2959 (29.6)
ARB	493 (10.5)	795 (15)	1288 (12.9)
Anti-platelets	1132 (24)	1639 (31)	2771 (27.7)
<b>Comorbidities before index</b>			
RA	138 (2.9)	137 (2.6)	275 (2.7)
Diabetes	462 (9.8)	728 (13.8)	1190 (11.9)
CKD	867 (18.4)	1090 (20.6)	1957 (19.6)
<b>CVD before index</b>			
Non-venous CVD	1031 (21.9)	1636 (30.9)	2667 (26.7)
VTE before index	144 (3.1)	324 (6.1)	468 (4.7)

**Table 2 - Characteristics of study population based on their initial exposure in the US**

	Unexposed	Tamoxifen	AI	Total
N	4667 (100)	2286 (100)	15074 (100)	22027 (100)
<b>Age at index date (yrs)</b>				
66-74	1538 (33)	897 (39.2)	7505 (49.8)	9940 (45.1)
75-84	1937 (41.5)	994 (43.5)	5894 (39.1)	8825 (40.1)
85+	1192 (25.5)	395 (17.3)	1675 (11.1)	3262 (14.8)
Median (IQR)	79 (73-85)	77 (72-83)	75 (71-81)	76 (71-82)
<b>Ethnicity</b>				
White	4002 (85.8)	2028 (88.7)	12782 (84.8)	18812 (85.4)
Black	360 (7.7)	102 (4.5)	1099 (7.3)	1561 (7.1)
Other	93 (2)	47 (2.1)	335 (2.2)	475 (2.2)
Asian	123 (2.6)	68 (3)	498 (3.3)	689 (3.1)
Hispanic	-	-	-	397 (1.8)
Native American	-	-	-	52 (.2)
Missing	-	-	-	41 (.2)
<b>SEER Region</b>				
North East	760 (16.3)	283 (12.4)	3320 (22)	4363 (19.8)
South	1023 (21.9)	605 (26.5)	3778 (25.1)	5406 (24.5)
North Central	695 (14.9)	448 (19.6)	1761 (11.7)	2904 (13.2)
West	2157 (46.2)	939 (41.1)	6130 (40.7)	9226 (41.9)
Missing	32 (.7)	11 (.5)	85 (.6)	128 (.6)
<b>Year of breast cancer</b>				
2008	847 (18.1)	414 (18.1)	2075 (13.8)	3336 (15.1)
2009	831 (17.8)	449 (19.6)	2140 (14.2)	3420 (15.5)
2010	729 (15.6)	368 (16.1)	2394 (15.9)	3491 (15.8)
2011	744 (15.9)	333 (14.6)	2625 (17.4)	3702 (16.8)
2012	756 (16.2)	350 (15.3)	2709 (18)	3815 (17.3)
2013	760 (16.3)	372 (16.3)	3131 (20.8)	4263 (19.4)
<b>Stage of breast cancer</b>				
Stage I	3034 (65)	1486 (65)	8379 (55.6)	12899 (58.6)
Stage II	1275 (27.3)	660 (28.9)	5267 (34.9)	7202 (32.7)
Stage III	358 (7.7)	140 (6.1)	1428 (9.5)	1926 (8.7)
<b>Grade of breast cancer</b>				
1	1522 (32.6)	765 (33.5)	4273 (28.3)	6560 (29.8)
2	2071 (44.4)	1109 (48.5)	7350 (48.8)	10530 (47.8)
3	853 (18.3)	324 (14.2)	2810 (18.6)	3987 (18.1)
Missing	221 (4.7)	88 (3.8)	641 (4.3)	950 (4.3)
<b>Cancer treatments</b>				
Taxane	570 (12.2)	162 (7.1)	2415 (16)	3147 (14.3)
Anthracyclines	259 (5.5)	68 (3)	820 (5.4)	1147 (5.2)
Trastuzumab	226 (4.8)	39 (1.7)	687 (4.6)	952 (4.3)
Other treatment	753 (16.1)	244 (10.7)	2992 (19.8)	3989 (18.1)
<b>Comorbidities</b>				
RA	185 (4)	103 (4.5)	547 (3.6)	835 (3.8)
CKD	383 (8.2)	155 (6.8)	1113 (7.4)	1651 (7.5)
Hypertension	3426 (73.4)	1612 (70.5)	11113 (73.7)	16151 (73.3)
Diabetes	1313 (28.1)	598 (26.2)	4545 (30.2)	6456 (29.3)
<b>CVD related treatment before index</b>				
Statins	1778 (38.1)	948 (41.5)	6988 (46.4)	9714 (44.1)
Hypertensives	169 (3.6)	83 (3.6)	577 (3.8)	829 (3.8)
ACEi	962 (20.6)	477 (20.9)	3251 (21.6)	4690 (21.3)
CCB	850 (18.2)	364 (15.9)	2696 (17.9)	3910 (17.8)
ARB	593 (12.7)	255 (11.2)	2063 (13.7)	2911 (13.2)
<b>Past CVD</b>				
Non venous CVD	2989 (64)	1281 (56)	8896 (59)	13166 (59.8)
VTE	162 (3.5)	31 (1.4)	385 (2.6)	578 (2.6)

\*Cell numbers within ethnicity suppressed due to some cells containing numbers  $\leq 11$

# 1 **FIGURE LEGENDS**

2 Figure 1 - Flow diagrams of study populations in the UK and US


3

4 Figure 2 - Adjusted HRs for the association between ever AI use compared with ever tamoxifen use  
5 and the risk of a range of clinical CVD outcomes in the UK and US


6


7 Figure 3 - Adjusted HRs, events, and crude rate per 1000 person-years for the association between  
8 ever exposure to endocrine therapy and a range of clinical CVD outcomes in the US

## UK flow diagram



## US flow diagram






\* UK results adjusted for the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-smoker); BMI (underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-drinker); IMD score (level 1-5 based on GP level IMD data); use of statins; use of ACE inhibitors; use of calcium channel blockers (CCB); use of angiotensin II receptor blockers (ARB); diabetes; chronic kidney disease; rheumatoid arthritis; systolic blood pressure (low/normal, pre-high, high); diastolic blood pressure (low/normal, pre-high, high); history of VTE; history of non-venous CVD year of breast cancer diagnosis; time since index (0-1yrs, 1-3yrs, 3-5yrs, 5+yrs); and current year.

US results adjusted for year of breast cancer diagnosis (2007-2013); age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native American, other); SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date (0-1yr, 1-3yrs, 3-5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-hypertensive drugs, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, diabetes, VTE, and non-venous CVD





\* Adjusted for year of breast cancer diagnosis (2007-2013); age at index date (66-74, 75-45, 85+); race (White, Black Asian, Hispanic, Native American, other); SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date (0-1yr, 1-3yrs, 3-5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-hypertensive drugs, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, diabetes, VTE, and non-venous CVD

\*\* Events and follow-up suppressed if number of events  $\leq 11$